Fiche personne
Coordonnées
ICANS | Institut cancérologie Strasbourg Europe
17 rue Albert Calmette
BP 23025
67033 STRASBOURG
03 68 76 66 66
Territoire
Alsace
Statut
Hospitalier
Publications
Influence of pneumatic transportation on the stability of monoclonal antibodies.
Coliat P, Erb S, Diemer H, Karouby D, Martin T, Banerjee M, Zhu C, Demarchi M, Cianférani S, Detappe A, Pivot X
Sci Rep. 2023 12 10;13(1):21875
Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review.
Moinard-Butot F, Nannini S, Fischbach C, Abdallahoui S, Demarchi M, Petit T, Bender L, Schott R
Cancers (Basel). 2023 10 11;15(20):
A propensity score-weighted study comparing a two- versus four-weekly pegylated liposomal doxorubicin regimen in metastatic breast cancer.
Bischoff H, Bigot C, Moinard-Butot F, Pflumio C, Fischbach C, Kalish M, Kurtz JE, Pierard L, Demarchi M, Karouby D, Coliat P, Pivot X, Petit T, Cox DG, Goepp L, Bender L, Trensz P
Breast Cancer Res Treat. 2022 12 23;:
Real-World Data on Newly Diagnosed -Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
Bini M, Quesada S, Meeus P, Rodrigues M, Leblanc E, Floquet A, Pautier P, Marchal F, Provansal M, Campion L, Causeret S, Gourgou S, Ray-Coquard I, Classe JM, Pomel C, De La Motte Rouge T, Barranger E, Savoye AM, Guillemet C, Gladieff L, Demarchi M, Rouzier R, Courtinard C, Romeo C, Joly F
Cancers (Basel). 2022 08 21;14(16):
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.
Paquette B, Kalbacher E, Mercier F, Lakkis Z, Doussot A, Turco C, Caputo E, Pili-Floury S, Royer B, Mansi L, Delroeux D, Demarchi M, Pivot X, Chauffert B, Clement E, Heyd B
Ann Surg Oncol. 2022 Jan 7;:
TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin and US-Herceptin in healthy male subjects.
Demarchi M, Coliat P, Mclendon K, Chung Shii Hii J, Feyaerts P, Ang F, Jaison L, Deforce F, Derde MP, Kim MJ, Park LS, Detappe A, Pivot X
Pharmacol Res Perspect. 2021 Aug;9(4):e00839
Status of Surgical Management of Borderline Ovarian Tumors in France: are Recommendations Being Followed? Multicentric French Study by the FRANCOGYN Group.
Lecointre L, Bund V, Sangnier E, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Demarchi M, Lavoué V, Akladios C
Ann Surg Oncol. 2021 Apr 26;:
A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M, Coliat P, Barthelemy P, Schott R, BenAbdelghani M, Kim M, Hii JCS, Feyaerts P, Ang FRX, Derde MP, Deforce F, Petit T, Schwabe C, Wynne C, Park LS, Pivot X
PLoS One. 2021 ;16(9):e0248222
Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C
Front Oncol. 2021 ;11:714551
F-FDG PET/CT Imaging of Peritoneal Fibrosis Mimicking Persistent Metastatic Ovarian Carcinoma.
Leroy-Freschini B, Lindner V, Boisramé T, Demarchi M
Nucl Med Mol Imaging. 2020 Oct;54(5):249-251
Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity.
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S
Br J Clin Pharmacol. 2020 Aug 12;:
Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN).
Bund V, Lecointre L, Velten M, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Demarchi M, Baldauf JJ, Ballester M, Lavoué V, Akladios C
J Clin Med. 2020 Jul 29;9(8):
Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol.
Mallard J, Hucteau E, Schott R, Petit T, Demarchi M, Belletier C, Ben Abdelghani M, Carinato H, Chiappa P, Fischbach C, Kalish-Weindling M, Bousinière A, Dufour S, Favret F, Pivot X, Hureau TJ, Pagano AF
Front Oncol. 2020 ;10:1304
Impact of neoadjuvant chemotherapy cycles on survival of patients with advanced ovarian cancer: A French national multicenter study (FRANCOGYN).
Lecointre L, Velten M, Lodi M, Saadeh R, Lavoué V, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Martin D, Baldauf JJ, Akladios C, Ballester M
Eur. J. Obstet. Gynecol. Reprod. Biol.. 2019 Dec 6;245:64-72
Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer.
Borel C, Regnier-Gavier O, Carinato H, Guihard S, Antoni D, Demarchi M, Sirlin F, Exinger D, Petit-Jean E, Thiery A, Bronner G, Schultz P, Flesch H, Frasie V, Prébay D, Petit T, Jung AC, Burgy M, Coliat P
Oncotarget. 2018 Dec 25;9(101):37581-37588
[Prevalence and management of pain in patients with metastatic cancer in Franche-Comté].
Dénommé F, Kroemer M, Montcuquet P, Nallet G, Thiery-Vuillemin A, Bazan F, Mouillet G, Villanueva C, Demarchi M, Stein U, Almotlak H, Chaigneau L, Curtit E, Meneveau N, Maurina T, Dobi E, Hon TN, Cals L, Mansi L, Verlut C, Pana-Katatali H, Caubet M, Paillard MJ, Limat S, Pivot X, Nerich V
Bull Cancer. 2016 Oct;103(10):849-860
Impact of Chemotherapy Beyond the Third Line in Patients With Recurrent Epithelial Ovarian Cancer.
Mansi L, Demarchi M, Bazan F, Delroeux D, Chaigneau L, Thiery-Vuillemin A, Bernhard S, Lakkis Z, Lakkis Z, Nerich V, Pivot X, Kalbacher E
Int. J. Gynecol. Cancer. 2016 Feb;26(2):261-7
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P
Ann Oncol. 2015 Jun;26(6):1194-1200
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X
Cancer Med. 2014 Dec;3(6):1502-11
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Fiteni F, Jary M, Monnien F, Nguyen T, Beohou E, Demarchi M, Dobi E, Fein F, Cleau D, Fratte S, Nerich V, Bonnetain F, Pivot X, Borg C, Kim S
BMC Gastroenterol. 2014 Aug 13;14:143
DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma.
Kim S, Jary M, Mansi L, Benzidane B, Cazorla A, Demarchi M, Nguyen T, Kaliski A, Delabrousse E, Bonnetain F, Letondal P, Bosset JF, Valmary-Degano S, Borg C
Ann Oncol. 2013 Dec;24(12):3045-50
Is extracapsular tumour spread a prognostic factor in patients with early breast cancer?
Dobi E, Bazan F, Dufresne A, Demarchi M, Villanueva C, Chaigneau L, Montcuquet P, Ivanaj A, Sautiere JL, Maisonnette-Escot Y, Cals L, Algros MP, Woronoff AS, Pivot X
Int J Clin Oncol. 2013 Aug;18(4):607-13
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Villanueva C, Romieu G, Salvat J, Chaigneau L, Merrouche Y, N'guyen T, Vuillemin AT, Demarchi M, Dobi E, Pivot X
Target Oncol. 2013 Jun;8(2):137-43
Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
Nerich V, Borg C, Villanueva C, Thiery-Vuillemin A, Helias P, Rohrlich PS, Demarchi M, Pivot X, Limat S
J Oncol Pharm Pract. 2013 Mar;19(1):8-17
Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.
Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C
Clin Colorectal Cancer. 2013 Mar;12(1):28-36
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cleau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C
BMC Cancer. 2013 Dec 27;13:611
Extravasation of liposomal doxorubicin induces irritant reaction without vesicant injury.
Curtit E, Chaigneau L, Pauchot J, Nguyen T, Nerich V, Bazan F, Thiery-Vuillemin A, Demarchi M, Pivot X, Villanueva C
Anticancer Res.. 2012 Apr;32(4):1481-3
Phase II trial of paclitaxel and uracil--tegafur in metastatic breast cancer. TEGATAX trial.
Villanueva C, Chaigneau L, Dufresne A, Thierry Vuillemin A, Stein U, Demarchi M, Bazan F, N'guyen T, Pivot X
Breast. 2011 Aug;20(4):329-33
Cabazitaxel: a novel microtubule inhibitor.
Villanueva C, Bazan F, Kim S, Demarchi M, Chaigneau L, Thiery-Vuillemin A, Nguyen T, Cals L, Dobi E, Pivot X
Drugs. 2011 Jul 9;71(10):1251-8
Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.
Lorgis V, Algros MP, Villanueva C, Chaigneau L, Thierry-Vuillemin A, Nguyen T, Demarchi M, Bazan F, Sautiere JL, Maisonnette-Lescot Y, Ringenbach F, Bontemps P, Pivot X
Breast. 2011 Jun;20(3):284-7
Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
Thiery-Vuillemin A, Dobi E, Nguyen T, Royer B, Montange D, Maurina T, Kalbacher E, Bazan F, Villanueva C, Demarchi M, Chaigneau L, Ivanaj A, Pivot X
Anticancer Drugs. 2010 Nov;21(10):958-62.
Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors.
Nerich V, Limat S, Demarchi M, Borg C, Rohrlich PS, Deconinck E, Westeel V, Villanueva C, Woronoff-Lemsi MC, Pivot X
Int J Med Inform. 2010 Oct;79(10):699-706.
An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma.
Montange D, Berard M, Demarchi M, Muret P, Piedoux S, Kantelip JP, Royer B
J Mass Spectrom. 2010 Jun;45(6):670-7.
Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study.
Guardiola E, Chauffert B, Delroeux D, Royer B, Heyd B, Combe M, Benoit L, Causeret S, Demarchi M, Magnin G, Mayer F, Tixier H, Pivot X
Anticancer Drugs. 2010 Mar;21(3):320-5.
Safety profile of new anticancer drugs.
Mansi L, Thiery-Vuillemin A, Nguyen T, Bazan F, Calcagno F, Rocquain J, Demarchi M, Villanueva C, Maurina T, Pivot X
Expert Opin Drug Saf. 2010 Mar;9(2):301-17.
Ixabepilone: a new active chemotherapy in the treatment of breast cancer.
Villanueva C, Vuillemin AT, Demarchi M, Bazan F, Chaigneau L, Pivot X
Womens Health (Lond Engl). 2009 Mar;5(2):115-21.
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M, Stein U, Royer B, Chauffert B, Pivot X
World J Surg Oncol. 2009 Feb 9;7:14.
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, Demarchi M, Borg C, Fagnoni-Legat C, Kantelip JP, Pivot X
Ann Oncol. 2008 Nov;19(11):1980-1.
Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
Pivot X, Villanueva C, Chaigneau L, Nguyen T, Demarchi M, Maurina T, Stein U, Borg C
Expert Opin Investig Drugs. 2008 Apr;17(4):593-9.
Anticancer therapy in patients with porphyrias: evidence today.
Thiery-Vuillemin A, Chaigneau L, Meaux-Ruault N, Villanueva C, N'guyen T, Maurina T, Stein U, Lorgis V, Demarchi M, Pivot X
Expert Opin Drug Saf. 2008 Mar;7(2):159-65.
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
Viel E, Demarchi MF, Chaigneau L, Nguyen T, Legat C, Stein U, Thiery-Vuillemin A, Limat S, Pivot X, Borg C
Am J Clin Oncol. 2008 Feb;31(1):89-94.
